Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia

Phase 1

• Conditions: Androgenetic Alopecia

• Registration Number: NCT02154503
• Lead Sponsor: Vancouver General Hospital

Brief Summary

Androgenetic Alopecia is the most common non scarring alopecia worldwide. Treatment of which has been limited with few options for medical and surgical treatment, the cost of the latter being prohibitive for many. Recently there have been several new modalities proposed as treatment, namely Microneedling and Platelet Rich Plasma.

Microneedling has been shown to overexpress hair growth factors which may enhance or stimulate miniaturized hairs to grow. It has also been shown to increase the absorption of topical products significantly. The exact mechanism of action of Microneedling is still being delineated.

In this study, we aim to do a half lesional study with global photographs and hair counts done at the start of , week four and week twelve. Patients would be needled once weekly after application of topical anaesthetic (5% EMLA). If by week six there is significant regrowth (\>30%), then total lesional needling will be done. Patients will only be using topical 5% Minoxidil throughout the study as this will prolong the effects of the regrowth.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-04
• Status Verified: 2014-05
• Study First Submitted: 2014-05-30
• Study First Submitted QC: 2014-06-02
• Last Update Submitted: 2014-06-02
• Study First Posted: 2014-06-03
• Last Update Posted: 2014-06-03
• Primary Completion: 2017-03
• Study Completion: 2017-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Male
• Target Recruitment: 20

Inclusion Criteria

1. Men between the ages 18-65.
2. Disease Stage: Norwood Hamilton IIIa-IV.
3. Length of time with disease < 10 years.

Exclusion Criteria

1. Must not have other concurrent hair disease.
2. Have not used any oral anti androgen (Finasteride or Dutasteride) in the past six months. If so, a washout period is needed. One month for Finasteride and three months for Dutasteride.
3. Patients under the age of 18.
4. Patients who are unable to offer consent.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Hair caliber diameter and hair counts will be measured on both the treated and untreated sides.	three months

Secondary Outcome Measures

Name	Time	Method
Adverse effects of the procedure will be recorded.	three months

Trial Locations

Locations (1)

The Skin Care Centre; 🇨🇦 Vancouver, British Columbia, Canada